Work Here?
About Fractyl Health
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Total Funding
$282.2M
Headquarters
Lexington, Kentucky
Founded
2010
Overview
Fractyl focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy designed to enhance the function of islet cells in the pancreas, which are essential for blood sugar regulation. By improving these cells, Fractyl aims to help patients achieve long-term remission from T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still awaiting full FDA approval. Unlike many competitors, Fractyl's approach emphasizes addressing the underlying issues of these diseases rather than just managing symptoms. The company's goal is to transform the treatment landscape for T2D and obesity, ultimately preventing and eliminating these conditions.
Simplify's Take
What believers are saying
- Growing demand for minimally invasive procedures boosts Fractyl's market potential.
- European diabetes care market offers lucrative opportunities for Revita DMR.
- Experienced leadership enhances Fractyl's commercial strategy and product launch readiness.
What critics are saying
- Competition from established companies like Novo Nordisk poses a threat.
- Regulatory challenges with FDA approval could delay Rejuva's market entry.
- Market volatility may impact the success of Fractyl's IPO.
What makes Fractyl Health unique
- Fractyl Health focuses on minimally invasive therapies for chronic diseases.
- Revita DMR rejuvenates the duodenum lining, improving patient health.
- Rejuva platform targets pancreatic islet cells for long-term T2D remission.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$282.2M
Meets
Industry Average
Funded Over
8 Rounds
Bessemer Venture Partners
General CatalystGrowth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 6%2 year growth
↑ 1%At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita(R) in patients with T2D in Germany
Fractyl Health, Inc.BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer.Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he has left a profound mark on the healthcare landscape.“We are delighted to welcome Adrian to Fractyl, where his breadth of commercial and strategic leadership experience will be instrumental as we prepare for the launch of our Revita® system,” said Dr. Harith Rajagopalan, CEO of Fractyl Health
BURLINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) - Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced promising new preclinical findings for the first clinical candidate in its Rejuva(R) pancreatic gene therapy platform.
Fractyl Health (Nasdaq: GUTS), announces pricing of initial public offering. ...
Fractyl Health, developing procedural and gene therapies for type 2 diabetes and obesity, filed an S-1 filing with the SEC on Thursday to raise up to $100 million in an initial public offering.
Fractyl Health is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Fractyl Health
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Total Funding
$282.2M
Headquarters
Lexington, Kentucky
Founded
2010
Fractyl Health is Hiring for 0 Jobs on Simplify!
Find jobs on Simplify and start your career today